Insights
Search Results
Client Highlights
4.02.26
Wilson Sonsini Advises View Point Medical on Acquisition by Merit Medical
On April 1, 2026, Merit Medical Systems, Inc., a global leader of healthcare technology, announced it has acquired View Point Medical, Inc. The aggregate transaction consideration, including the assumption of View Point liabilities, is approximately $140 million. Wilson Sonsini Goodrich & Rosati advised View Point on the transaction.
Client Highlights
3.09.26
Wilson Sonsini Advises Lead Investor on SHINE’s $240 Million Equity Funding
On February 27, 2026, SHINE Technologies, a nuclear fusion company, announced it has raised $240 million in equity funding led by NantWorks founder Dr. Patrick Soon-Shiong, with additional participation from Fidelity Management & Research Company, Sumitomo Corporation of Americas, Pelican Energy Partners, Deerfield Management, Oaktree Capital Management, and other existing investors. Wilson Sonsini Goodrich & Rosati advised lead investor OZ Shine LLC—a new investment company led by Dr. Soon-Shiong—on the transaction.
Client Highlights
5.07.24
Wilson Sonsini Advises SR One, Norwest Venture Partners, and Delos Capital in Zenas BioPharma's Upsized $200 Million Series C
On May 7, 2024, Zenas BioPharma, a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology-directed therapies, announced an upsized $200 million Series C preferred stock financing led by SR One, along with NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences and Longitude Capital. Also participating in the financing are new investors Federated Hermes Kaufmann Funds and Arrowmark Partners, along with existing investors, Fairmount, Wellington Management, Rock Springs Capital, Pivotal bioVenture Partners, Vivo Capital, Quan Venture Fund, and Superstring Capital. Wilson Sonsini Goodrich & Rosati advised SR One, Norwest Venture Partners, and Delos Capital on the transaction.
Client Highlights
5.02.24
Firm Advises Novo Holdings on Reunion Neuroscience’s $103 Million Series A
On May 2, 2024, Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, announced the close of a $103 million Series A financing co-led by Novo Holdings and MPM BioImpact, with participation from Arkin Bio Capital, Mitsui & Co. Global Investment, Plaisance Capital, FemHealth Ventures, and Palo Santo. Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction.
Client Highlights
1.03.24
Wilson Sonsini Advises ImmunityBio on $320 Million Investment
On January 2, 2024, ImmunityBio, Inc., a clinical-stage immunotherapy company announced an up to $320 million royalty financing and equity investment in the company by Oberland Capital, with $210 million of gross proceeds received at closing on December 29, 2023. The additional capital provides significant financial resources for ImmunityBio to accelerate its commercialization efforts in anticipation of a potential regulatory approval, as well as to expand its pipeline within the broader urological cancer space. The proceeds will also be used to fund ongoing business operations and clinical trials expanding N-803 (Anktiva®) indications into multiple solid tumors. Wilson Sonsini Goodrich & Rosati represented ImmunityBio in the transaction.
Client Highlights
7.31.23
Wilson Sonsini Advises Versant Ventures and New Enterprise Associates on Nexo Therapeutics' $60 Million Series A
On July 26, 2023, Nexo Therapeutics (Nexo), a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies, emerged from stealth with $60 million Series A financing led by founding investor Versant Ventures with participation from New Enterprise Associates and Cormorant Asset Management. Wilson Sonsini Goodrich & Rosati advised Versant Ventures and New Enterprise Associates on the deal.
Client Highlights
1.26.23
Firm Advises Pacific Biosciences of California on Upsized Stock Offering
On January 24, 2023, life sciences technology company Pacific Biosciences of California Inc announced that it has priced a 17.5 million share secondary stock offering at $10 per share. The transaction will raise $175 million, which was upsized from the original size of $150 million. Wilson Sonsini Goodrich & Rosati advised Pacific Biosciences on the transaction.
Client Highlights
11.10.22
Firm Advises Investors on Zenas BioPharma’s $118 Million Series B Financing
On November 7, 2022, global pharmaceutical company Zenas BioPharma announced a $118 million Series B equity financing that will be used to develop and bring to market immune-based therapies. Wilson Sonsini Goodrich & Rosati advised lead investor Enavate Sciences and new investor Longitude Capital in the financing.